A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

What is the purpose of this trial?

This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may block cancer growth in different ways by targeting certain cells.


Participation Guidelines

Ages: 18 years and older

Gender: Both


National Cancer Institute

Start Date: 04/20/2017

End Date: 05/31/2018

Last Updated: 06/01/2018

Study HIC#: 1608018198

Get Involved

For more information about this study, contact:
Laura Leary
laura.leary@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Francine Foss

Principal Investigator

Sub-Investigators